Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration.
The CSF levels of somatostatin-LI (SLI), neuropeptide Y (NPY-LI) and Delta Sleep Inducing Peptide (DSIP-LI) have been measured in patients with dementia of Alzheimer type (DAT) and dementia with frontotemporal degeneration of non-Alzheimer type (FTD). The distribution pattern of cortical degeneration differs between these two types of dementia. DAT shows degeneration of mainly temporo-parietal and temporo-limbic structures, whereas FTD discloses its main degeneration in the frontotemporal regions (Brun, 1987). The somatostatin-LI was significantly reduced both in DAT and FTD. NPY-LI showed a significant reduction in DAT but not in FTD. A tendency to a reduction with duration of the disease was observed in DAT whereas the contrary was noted in FTD. The DSIP-LI levels were reduced in DAT and slightly increased in FTD. The study provides an evidence of neurochemical differences between the two primary degenerative dementias.
Minthon
L
L
Department of Psychogeriatrics, University of Lund, Sweden.
Edvinsson
L
L
Ekman
R
R
Gustafson
L
L
D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D003701:Delta Sleep-Inducing Peptide / Q000378:metabolism; D003704:Dementia / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005625:Frontal Lobe / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000378:metabolism; D009479:Neuropeptides / Q000378:metabolism*; D013004:Somatostatin / Q000378:metabolism; D013702:Temporal Lobe / Q000473:pathology*
D009478:Neuropeptide Y; D009479:Neuropeptides; D013004:Somatostatin; D003701:Delta Sleep-Inducing Peptide